Drug intelligence / Profile preview

hIgG8.8-MTI2

Development stage: Preclinical
Lead developer: Pfizer
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hIgG8.8-MTI2 is an experimental antibody-drug conjugate (ADC) developed by Pfizer, consisting of a humanized control IgG antibody (hIgG8.8) conjugated to a microtubule inhibitor payload (MTI2). In preclinical studies, it was utilized as a non-targeting control ADC to evaluate the efficacy and specificity of IL-13Rα2-targeted ADCs (such as hAB08-MTI2) in cancer models, including glioblastoma, ovarian, and pancreatic cancers. As a control, it lacks the specific binding affinity for tumor-associated antigens, serving to differentiate target-mediated cytotoxicity from off-target effects of the payload.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on hIgG8.8-MTI2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hIgG8.8-MTI2.

Explore the full profile